• 한국콘텐츠학회논문지
• /
• 제21권8호
• /
• pp.691-701
• /
• 2021

본 연구는 COPD 환자를 대상으로 보편적 건강문해력인 의료정보 문해력, COPD 특이 건강문해력인 COPD 관련 건강문해력 및 자가관리 이행 정도를 확인하고, 의료정보 문해력, COPD 관련 건강문해력과 자가관리 이행 정도와의 상관관계를 파악하였다. COPD 환자의 의료정보 문해력은 60.45±9.42점으로 중학교 1~2학년 수준이었고 COPD 관련 건강문해력이 의료정보 문해력보다 평균 점수가 낮았다. COPD 관련 건강문해력과 자가관리 이행 정도는 통계적으로 유의한 상관관계를 보였다. COPD 환자를 간호하는 간호사는 대상자의 건강문해력을 정확히 이해하고 의사소통하는 것이 필요하다고 생각된다. COPD 관련 건강문해력 증진이 자가관리 이행을 높일 수 있으므로 건강정보를 제공하거나 교육 시 COPD의 건강문해력을 증진시킬 수 있는 전략 개발이 필요하다.

• 한국정보과학회 언어공학연구회:학술대회논문집(한글 및 한국어 정보처리)
• /
• 한국정보과학회언어공학연구회 2017년도 제29회 한글 및 한국어 정보처리 학술대회
• /
• pp.251-254
• /
• 2017

본 연구에서는 COPD와 기존에 연관이 있는 것으로 알려진 바이오마커 이외의 새로운 바이오마커를 찾고자 한다. Pubmed Data에서 선정한 암 관련 바이오마커를 추출하여 COPD와 암 관련 바이오마커의 관계를 파악하는 데이터로 사용한다. 그리고 워드 임베딩 모델 중 Word2vec을 사용하여 워드 임베딩 한다. 워드 임베딩한 K차원의 COPD와 암 관련 바이오마커를 t-SNE를 사용하여 시각화한다. 또한 코사인 유사도를 이용하여 COPD와 암 관련 바이오마커의 유사도를 측정한다. 그리고 코사인 유사도와 t-SNE 결과를 이용하여 COPD와 암 관련 바이오마커와의 상관관계를 파악할 수 있으며, 암 관련 바이오마커와 COPD 관련 바이오마커를 비교 하여 기존의 COPD와 연관이 있다고 알려진 바이오마커 이외의 새로운 바이오마커를 찾을 수 있다.

• 한국어정보학회:학술대회논문집
• /
• 한국어정보학회 2017년도 제29회 한글및한국어정보처리학술대회
• /
• pp.251-254
• /
• 2017

본 연구에서는 COPD와 기존에 연관이 있는 것으로 알려진 바이오마커 이외의 새로운 바이오마커를 찾고자 한다. Pubmed Data에서 선정한 암 관련 바이오마커를 추출하여 COPD와 암 관련 바이오마커의 관계를 파악하는 데이터로 사용한다. 그리고 워드 임베딩 모델 중 Word2vec을 사용하여 워드 임베딩 한다. 워드 임베딩한 K차원의 COPD와 암 관련 바이오마커를 t-SNE를 사용하여 시각화한다. 또한 코사인 유사도를 이용하여 COPD와 암 관련 바이오마커의 유사도를 측정한다. 그리고 코사인 유사도와 t-SNE 결과를 이용하여 COPD와 암 관련 바이오마커와의 상관관계를 파악할 수 있으며, 암 관련 바이오마커와 COPD 관련 바이오마커를 비교 하여 기존의 COPD와 연관이 있다고 알려진 바이오마커 이외의 새로운 바이오마커를 찾을 수 있다.

• Tuberculosis and Respiratory Diseases
• /
• 제85권4호
• /
• pp.302-312
• /
• 2022

Chronic obstructive pulmonary disease (COPD) is a complex and heterogeneous disease. Not all patients with COPD respond to available drugs. Identifying respondents to therapy is critical to delivering the most appropriate treatment and avoiding unnecessary medication. Recognition of individual patients' dominant characteristics by phenotype is a useful tool to better understand their disease and tailor treatment accordingly. To look for a suitable phenotype, it is important to understand what makes COPD complex and heterogeneous. The pathology of COPD includes small airway disease and/or emphysema. Thus, COPD is not a single disease entity. In addition, there are two types (panlobular and centrilobular) of emphysema in COPD. The coexistence of different pathological subtypes could be the reason for the complexity and heterogeneity of COPD. Thus, it is necessary to look for the phenotype based on the difference in the underlying pathology. Review of the literature has shown that clinical manifestation and therapeutic response to pharmacological therapy are different depending on the presence of computed tomography-defined airway wall thickening in COPD patients. Defining the phenotype of COPD based on the underlying pathology is encouraging as most clinical manifestations can be distinguished by the presence of increased airway wall thickness. Pharmacological therapy has shown significant effect on COPD with airway wall thickening. However, it has limited use in COPD without an airway disease. The phenotype of COPD based on the underlying pathology can be a useful tool to better understand the disease and adjust treatment accordingly.

• Tuberculosis and Respiratory Diseases
• /
• 제84권1호
• /
• pp.35-45
• /
• 2021

Globally, cardiovascular diseases and chronic obstructive pulmonary disease (COPD) are the leading causes of the non-communicable disease burden. Overlapping symptoms such as breathing difficulty and fatigue, with a lack of awareness about COPD among physicians, are key reasons for under-diagnosis and resulting sub-optimal care relative to COPD. Much has been published in the past on the pathogenesis and implications of cardiovascular comorbidities in COPD. However, a comprehensive review of the prevalence and impact of COPD management in commonly encountered cardiac diseases is lacking. The purpose of this study was to summarize the current knowledge regarding the prevalence of COPD in heart failure, ischemic heart disease, and atrial fibrillation. We also discuss the real-life clinical presentation and practical implications of managing COPD in cardiac diseases. We searched PubMed, Scopus, EMBASE, and Google Scholar for studies published 1981-May 2020 reporting the prevalence of COPD in the three specified cardiac diseases. COPD has high prevalence in heart failure, atrial fibrillation, and ischemic heart disease. Despite this, COPD remains under-diagnosed and under-managed in the majority of patients with cardiac diseases. The clinical implications of the diagnosis of COPD in cardiac disease includes the recognition of hyperinflation (a treatable trait), implementation of acute exacerbations of COPD (AECOPD) prevention strategies, and reducing the risk of overuse of diuretics. The pharmacological agents for the management of COPD have shown a beneficial effect on cardiac functions and mortality. The appropriate management of COPD improves the cardiovascular outcomes by reducing hyperinflation and preventing AECOPD, thus reducing the risk of mortality, improving exercise tolerance, and quality of life.

• Tuberculosis and Respiratory Diseases
• /
• 제66권3호
• /
• pp.186-191
• /
• 2009

연구배경: 골다공증은 만성폐쇄성폐질환 환자의 중요한 동반질환 중 하나이다. 저자들은 COPD 환자에서 골다공증의 유병률과 위험인자를 알아 보고자 하였다. 방 법: 안정 상태인 COPD 환자 51명과 이들과 나이와 성별을 일치시킨 대조군 41명에서 요추골과 대퇴골의 골밀도를 측정하였다. 임상기록과 검사결과를 검토하여, COPD 환자에서 골다공의 위험인자를 분석하였다. 결 과: COPD 환자에서, T점수가 -2.5 이하인, 골다공증의 유병률은 47%였고, 대조군에서 32%였다. 특히 대퇴골목의 T점수를 기준으로 한 골다공증의 유병률은 COPD 환자에서 대조군에 비해 유의하게 높았다(26% vs. 5%; p=0.006). COPD 환자의 요추와(p=0.025) 대퇴골목의 평균 T 점수는 대조군보다 유의하게 낮았다(p=0.001). COPD 환자에서 $FEV_1$의 정상예측치에 대한 비율과(p=0.019; odds ratio [OR], 0.955; 95% confidence interval [CI], 0.919-0.993) 연령이 골다공증 발생과 관련된 독립적인 위험인자였다(p=0.024; OR, 1.144; 95% CI, 1.018-1.287). 결 론: COPD 환자에서 골다공증의 유병률은 연령과 성별을 일치시킨 대조군보다 높다. 특히 대퇴골의 T점수가 요추보다 COPD 환자와 대조군의 골밀도의 차이를 더 분명하게 보여 주었다. COPD 환자에서 $FEV_1$이 낮을수록, 나이가 많을수록 골다공증 발생 위험이 크게 증가한다.

• 건강소식
• /
• 제28권9호통권310호
• /
• pp.28-29
• /
• 2004

현재 흡연으로 인한 COPD(만성폐쇄성폐질환)의 국내 의료비 부담이 심각한 것으로 드러났다. COPD 의료비 증가로 인한 경제적 부담감도 심각하지만, 천식 등으로 오인되는 COPD 환자 등 잠재환자의 증가와 더불어 COPD로 인한 사회경제적 손실도 더욱 커질 전망이다.

• Journal of Nutrition and Health
• /
• 제50권6호
• /
• pp.585-594
• /
• 2017

Purpose: Food intake of COPD patients decreases because of appetite loss, depression, and breathing problems while eating, which increase the likelihood of patients becoming malnourished. This study investigated the nutrient intake and dietary quality of people with and without COPD in Korea. Methods: There were 2,160 adults aged 50 and over who participated in the $5{\sim}6^{th}$ Korea National Health and Nutrition Examination Survey. The subjects were divided into the COPD group and non-COPD group according to the rate of forced expiratory volume at 1 second (FEV1) against forced vital capacity (FVC). Consumption of food and nutrients were calculated based on the nutrition examination survey. Statistical analyses were conducted using SPSS 19.0. Results: Among individuals in their 50s, intake of vitamin $B_1$ in the COPD group was significantly less than the NCOPD group, while intake of sodium in the COPD group was significantly greater than the NCOPD group. Among individuals in their 60s, the energy intake of the COPD group was significantly less than that of the NCOPD group. The COPD group showed significantly less intake of vitamin $B_1$ and vitamin C, but greater intake of sodium than the NCOPD group. In the group aged 70 and over, The COPD group had significantly less intake of vitamin $B_1$ than the NCOPD group and showed lower nutrient adequacy ratio values in protein, vitamin $B_1$, vitamin $B_2$, and iron than the NCOPD group. Conclusion: The COPD group consumed less energy and certain nutrients, and their dietary quality was poor compared to the NCOPD group. Thus, more detailed research is required to understand the concrete relationship between COPD and malnutrition.

• Tuberculosis and Respiratory Diseases
• /
• 제80권3호
• /
• pp.226-229
• /
• 2017

Chronic obstructive pulmonary disease (COPD) had been considered the only major disease that is continuing to increase in prevalence. There were a few studies about the change of the prevalence of COPD, which showed the prevalence of COPD did not increase. In this review, we report on the trends in the prevalence of COPD in Korea using the data from Korea National Health and Nutrition Examination Survey (KNHANES). The prevalence of COPD in 2015 was 13.4% (male, 21.6%; female, 5.8%). The prevalence of COPD did not change much, which ranged from 13.1% to 14.6% during the period from 2010 to 2015. Among the subjects found to have COPD by spirometry, only 2.8% had been diagnosed as COPD by physicians during the period from 2011 and 2015. In conclusion, the prevalence of COPD did not change significantly during the period from 2010 to 2015. And most COPD patients still had not been diagnosed by physicians and consequently had not been treated appropriately.

• Experimental and Molecular Medicine
• /
• 제50권11호
• /
• pp.9.1-9.10
• /
• 2018

Although the positive effects of recombinant fibroblast growth factor-2 (rFGF-2) in chronic obstructive pulmonary disease (COPD) have been implicated in previous studies, knowledge of its role in COPD remains limited. The mechanism of FGF2 in a COPD mouse model and the therapeutic potential of rFGF-2 were investigated in COPD. The mechanism and protective effects of rFGF-2 were evaluated in cigarette smoke-exposed or elastase-induced COPD animal models. Inflammation was assessed in alveolar cells and lung tissues from mice. FGF-2 was decreased in the lungs of cigarette smoke-exposed mice. Intranasal use of rFGF-2 significantly reduced macrophage-dominant inflammation and alveolar destruction in the lungs. In the elastase-induced emphysema model, rFGF-2 improved regeneration of the lungs. In humans, plasma FGF-2 was decreased significantly in COPD compared with normal subjects (10 subjects, P = 0.037). The safety and efficacy of inhaled rFGF-2 use was examined in COPD patients, along with changes in respiratory symptoms and pulmonary function. A 2-week treatment with inhaled rFGF-2 in COPD (n = 6) resulted in significantly improved respiratory symptoms compared with baseline levels (P < 0.05); however, the results were not significant compared with the placebo. The pulmonary function test results of COPD improved numerically compared with those in the placebo, but the difference was not statistically significant. No serious adverse events occurred during treatment with inhaled rFGF-2. The loss of FGF-2 production is an important mechanism in the development of COPD. Inhaling rFGF-2 may be a new therapeutic option for patients with COPD because rFGF-2 decreases inflammation in lungs exposed to cigarette smoke.